| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.shukrapharmaceuticals.com | |
| Market Cap | 408.98 Cr. | |
| Enterprise Value(EV) | 411.29 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 4.23 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 22.07 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 19.76 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 4.73 | Calculated using Price: 93.40 |
| Dividend Yield | 0.54 | Period Ending 2023-03 |
| No. of Shares Subscribed | 4.38 Cr. | 43,787,944 Shares |
| FaceValue | 10 | |
| About Shukra Pharmaceuticals Ltd. | ||
| The company is engaged in the business of manufacturing and trading of pharmaceuticals Products, laboratory testing. | ||
| 1 Day |
|
+1.97% |
| 1 Week |
|
+12.41% |
| 1 Month |
|
+7.72% |
| 3 Month |
|
+196.51% |
| 6 Month |
|
+315.85% |
| 1 Year |
|
+348.82% |
| 2 Year |
|
+2607.25% |
| 5 Year |
|
+2893.59% |
| 10 Year |
|
+116650.0% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0.94 | 0.85 | 3.51 | 3.55 | 3.04 | 0.23 | 1.21 | 4.7 | 21.16 | |
| Return on Capital Employed (%) | 1.83 | 2.4 | 7.41 | 5.94 | 3.62 | 0.77 | 0.54 | 5.79 | 18.85 | |
| Return on Assets (%) | 0.72 | 0.67 | 2.78 | 2.44 | 1.76 | 0.11 | 0.54 | 2.12 | 8.01 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 14 | 14 | 15 | 15 | 15 | 15 | 16 | 16 | 25 | 44 | |
| Non Curr. Liab. | 3 | 2 | 3 | 6 | 9 | 11 | 13 | 6 | 7 | 5 | |
| Curr. Liab. | 1 | 1 | 2 | 3 | 4 | 7 | 7 | 12 | 43 | 25 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 74 | |
| Non Curr. Assets | 11 | 11 | 12 | 16 | 17 | 19 | 20 | 19 | 22 | 22 | |
| Curr. Assets | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 52 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 74 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 110 | |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
| Total Income | 4 | 5 | 5 | 5 | 6 | 12 | 12 | 21 | 60 | 112 | |
| Total Expenditure | -3 | -4 | -4 | -4 | -4 | -10 | -10 | -18 | -53 | -91 | |
| PBIDT | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 7 | 21 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Depreciation | -1 | 0 | 0 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | |
| Taxation | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | -1 | 0 | 0 | ||||||||
| PAT | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -3 | -2 | 3 | 0 | 1 | 0 | 1 | 1 | 8 | 3 | |
| Cash Fr. Inv. | 2 | 1 | 0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | |
| Cash Fr. Finan. | 2 | 1 | -1 | 3 | 2 | 2 | 2 | -7 | 5 | ||
| Net Change | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 4 | |
| Cash & Cash Eqvt | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 4 |
|
Fri, 26 Apr 2024
Compliance Certificate For Period Ended March 31 2024 Compliance certificate for period ended March 31 2024 |
|||||||||||||||||||||
|
Thu, 25 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Arpita Kabra Designation: Company Secretary EmailId: info@shukrapharmaceuticals.com Name of the Chief Financial Officer: Mehul Patel Designation: Chief Financial Officer EmailId: info@shukrapharmaceuticals.com Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Thu, 25 Apr 2024
Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Of The Company The Company has received approval from shareholders to issue bonus shares through postal ballot on April 03rd 2024 and the BSE In Principle approval received on 18th March 2024 bearing letter no: LOD/Bonus/BN-IP/TT/1444/2023-24. The Board of Directors in their meeting held today has approved allotment of 3 28 40 958 shares having face value of Rs. 10/-(Rupees Ten Only) each in ratio of 3(Three) new Equity shares for every 1(One) Equity shares held by the shareholders as on record date i.e. 20th April 2024. |
| Fri, 26 Apr 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Opening at High
|
Opening at Low
|
